Ironwood abandons deal with AstraZeneca for lesinurad, once hoped to be a gout blockbuster

Ironwood abandons deal with AstraZeneca for lesinurad, once hoped to be a gout blockbuster
Ironwood Pharmaceuticals has decided to walk away from its 2016 deal to license AstraZeneca’s billion-dollar gout treatment lesinurad in the U.S., following poor market performance of the drug, as Ironwood continues its march toward splitting into two separate public companies next year.
Source: FierceMedicalDevices News
Ironwood abandons deal with AstraZeneca for lesinurad, once hoped to be a gout blockbuster